MX341368B - Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn. - Google Patents
Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn.Info
- Publication number
- MX341368B MX341368B MX2011010675A MX2011010675A MX341368B MX 341368 B MX341368 B MX 341368B MX 2011010675 A MX2011010675 A MX 2011010675A MX 2011010675 A MX2011010675 A MX 2011010675A MX 341368 B MX341368 B MX 341368B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- dna damaging
- damaging agents
- checkpoint kinase
- potentiating
- Prior art date
Links
- 239000012623 DNA damaging agent Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000003389 potentiating effect Effects 0.000 title abstract 2
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 title 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 title 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16856309P | 2009-04-11 | 2009-04-11 | |
| PCT/US2010/030634 WO2010118390A1 (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011010675A MX2011010675A (es) | 2012-03-16 |
| MX341368B true MX341368B (es) | 2016-08-17 |
Family
ID=42651200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010675A MX341368B (es) | 2009-04-11 | 2010-04-09 | Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2416773B1 (https=) |
| JP (2) | JP5805071B2 (https=) |
| KR (1) | KR101676062B1 (https=) |
| CN (1) | CN102612365B (https=) |
| AU (1) | AU2010233122B2 (https=) |
| BR (1) | BRPI1013920A2 (https=) |
| CA (1) | CA2758300C (https=) |
| ES (1) | ES2608656T3 (https=) |
| IL (1) | IL215709A (https=) |
| MX (1) | MX341368B (https=) |
| NZ (1) | NZ596125A (https=) |
| RU (1) | RU2567044C2 (https=) |
| SG (3) | SG10201404012RA (https=) |
| WO (1) | WO2010118390A1 (https=) |
| ZA (1) | ZA201108273B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP6606428B2 (ja) | 2013-10-11 | 2019-11-13 | 国立大学法人 東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| TW202043198A (zh) * | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| KR102285996B1 (ko) * | 2019-08-08 | 2021-08-05 | 차의과학대학교 산학협력단 | 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도 |
| WO2021113661A1 (en) | 2019-12-05 | 2021-06-10 | Seagen Inc. | Amorphous and polymorphic form of a specific chk1 inhibitor |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| EP1667684A1 (en) * | 2003-09-17 | 2006-06-14 | ICOS Corporation | Use of chk1 inhibitors to control cell proliferation |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| CN101415417A (zh) * | 2006-04-04 | 2009-04-22 | 辉瑞产品公司 | (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法 |
| WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
-
2010
- 2010-04-09 SG SG10201404012RA patent/SG10201404012RA/en unknown
- 2010-04-09 CA CA2758300A patent/CA2758300C/en active Active
- 2010-04-09 MX MX2011010675A patent/MX341368B/es active IP Right Grant
- 2010-04-09 NZ NZ596125A patent/NZ596125A/xx not_active IP Right Cessation
- 2010-04-09 CN CN201080025806.6A patent/CN102612365B/zh not_active Expired - Fee Related
- 2010-04-09 BR BRPI1013920A patent/BRPI1013920A2/pt not_active Application Discontinuation
- 2010-04-09 KR KR1020117026769A patent/KR101676062B1/ko not_active Expired - Fee Related
- 2010-04-09 JP JP2012504909A patent/JP5805071B2/ja not_active Expired - Fee Related
- 2010-04-09 RU RU2011145773/15A patent/RU2567044C2/ru active
- 2010-04-09 SG SG2011075520A patent/SG175242A1/en unknown
- 2010-04-09 WO PCT/US2010/030634 patent/WO2010118390A1/en not_active Ceased
- 2010-04-09 SG SG10201900212QA patent/SG10201900212QA/en unknown
- 2010-04-09 AU AU2010233122A patent/AU2010233122B2/en not_active Ceased
- 2010-04-09 EP EP10721579.0A patent/EP2416773B1/en active Active
- 2010-04-09 ES ES10721579.0T patent/ES2608656T3/es active Active
-
2011
- 2011-10-11 IL IL215709A patent/IL215709A/en active IP Right Grant
- 2011-11-10 ZA ZA2011/08273A patent/ZA201108273B/en unknown
-
2014
- 2014-07-29 JP JP2014153687A patent/JP2014198741A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP5805071B2 (ja) | 2015-11-04 |
| SG175242A1 (en) | 2011-11-28 |
| SG10201900212QA (en) | 2019-02-27 |
| ZA201108273B (en) | 2013-07-31 |
| MX2011010675A (es) | 2012-03-16 |
| JP2014198741A (ja) | 2014-10-23 |
| CA2758300A1 (en) | 2010-10-14 |
| IL215709A (en) | 2017-06-29 |
| RU2011145773A (ru) | 2013-05-20 |
| CN102612365B (zh) | 2017-04-12 |
| ES2608656T3 (es) | 2017-04-12 |
| BRPI1013920A2 (pt) | 2016-04-05 |
| KR20120004523A (ko) | 2012-01-12 |
| JP2012523435A (ja) | 2012-10-04 |
| AU2010233122A1 (en) | 2011-11-24 |
| RU2567044C2 (ru) | 2015-10-27 |
| IL215709A0 (en) | 2012-01-31 |
| SG10201404012RA (en) | 2014-09-26 |
| KR101676062B1 (ko) | 2016-11-14 |
| AU2010233122B2 (en) | 2015-09-17 |
| CA2758300C (en) | 2017-07-25 |
| NZ596125A (en) | 2012-08-31 |
| WO2010118390A1 (en) | 2010-10-14 |
| CN102612365A (zh) | 2012-07-25 |
| EP2416773A1 (en) | 2012-02-15 |
| EP2416773B1 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341368B (es) | Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn. | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| TN2009000400A1 (en) | Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha | |
| UA115320C2 (uk) | Інгібітори кінази | |
| MX2009009786A (es) | Inhibidores de la via de hedgehog. | |
| UA98141C2 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| UY33498A (es) | Combinaciones de inhibidores de quinasas para el tratamiento de cancer | |
| EA201070237A1 (ru) | Четвертичные опиоидные карбоксамиды | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| UA106748C2 (uk) | Похідні проліну як інгібітори катепсину | |
| JO3073B1 (ar) | مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3 | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| PH12012502129A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| EP1962839A4 (en) | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER | |
| IN2012DN00765A (https=) | ||
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| MX2009010483A (es) | 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas. | |
| ES2530755T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| WO2011038924A3 (en) | Proteasome inhibitors for treating cancer | |
| ES2530436T3 (es) | Combinación | |
| UA33293U (ru) | Способ лечения хронического эндометрита | |
| EP1891082A4 (en) | NEW INHIBITORS OF PYRUVATE KINASE AS THERAPEUTIC AGENTS AGAINST CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |